WebDec 28, 2024 · By John Vandermosten, CFA TSX:HBP.TO OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT First Quarter Fiscal Year 2024 Operational and Financial … WebOct 15, 2024 · RICHMOND HILL, ON / ACCESSWIRE / October 15, 2024 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention ...
HBP.TO: LDOS006 New Sites Open - Yahoo Finance
WebBiotech Opportunity Fund managed by CAIAC Fund Management AG acquired 19.8% stake in Helix BioPharma Corp. (TSX:HBP) for CAD 13.2 million. Sep 01. New 90-day low - … WebApr 7, 2024 · Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the TSX under the symbol "HBP". For more information, please contact: Helix … small home office desk with keyboard tray
Helix BioPharma Corp.: Helix Biopharma Corp. Announces …
WebApr 9, 2024 · Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and … WebApr 22, 2024 · VANCOUVER, BC / ACCESSWIRE / April 22, 2024 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Company") (TSX: HBP) at a price of $0.26 per Common Share by way of non-brokered private placement for an aggregate subscription … WebMar 11, 2024 · RICHMOND HILL, ON / ACCESSWIRE / March 11, 2024 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of ... sonic chemical plant zone theme